ClinicalTrials.gg

Program

lutikizumab

Also written as “Lutikizumab”, “ABT-981” and “Lutikizumab Dose A”.

In AbbVie's pipeline, IL-1a / 1b. Its studies are mostly in Hidradenitis Suppurativa · Osteoarthritis · Arthritis, Psoriatic · Arthritis, Rheumatoid · Crohn Disease, led by AbbVie.

Furthest: phase 3, since Jun 17, 202412 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie128 open or runningphase 3since Jun 17, 2024Aug 1, 2012Dec 2026phase 3 · NCT06468228
  • Named in AbbVie’s own pipeline as Lutikizumab, phase 3, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 1, 2012First study: phase 1 study in OsteoarthritisFirst studyNCT01668511 · 36 enrolled · United States
  2. Mar 13, 2014Phase 2 study in Osteoarthritis, KneeNCT02087904 · 350 enrolled
  3. Mar 5, 2015Phase 2 study in OsteoarthritisNCT02384538 · 132 enrolled
  4. Nov 29, 2021Phase 2 study in Hidradenitis SuppurativaNCT05139602 · 210 enrolled · United States, Australia, Canada and more
  5. Sep 28, 2023Phase 1 study in Healthy VolunteersNCT06067568 · 50 enrolled · United States
  6. Oct 2, 2023Phase 2 study in Colitis, UlcerativeNCT06257875 · 156 enrolled · United States, Australia, Austria and more
  7. Jun 17, 2024Phase 3 study in Hidradenitis SuppurativaNCT06468228 · 1,400 enrolled · United States, Argentina, Australia and more
  8. Jul 24, 2024Phase 2 study in Hidradenitis SuppurativaNCT06524635 · 60 planned · United States
  9. Aug 8, 2024Phase 2 study in Crohn DiseaseNCT06548542 · 590 planned · United States, Austria, Belgium and more
  10. Dec 2, 2024Phase 2 study in Dermatitis, AtopicNCT06718101 · 83 enrolled · United States, Japan, South Korea and more
  11. Mar 4, 2025Phase 2 study in Arthritis, PsoriaticNCT06865105 · 300 planned · United States, Canada, Czechia and more
  12. May 7, 2025Phase 2 study in Arthritis, RheumatoidNCT06972446 · 180 planned · United States, Canada, Czechia and more
  13. Nov 9, 2026Primary completion moved from 2027-12 to 2029-08Date moved laterphase 2 · +20 months · NCT06865105

Ahead

  1. Dec 2026Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06468228
  2. Feb 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT06972446
  3. Feb 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT06524635
  4. May 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT06718101

TargetBeta

“IL-1a / 1b”the company's pipeline, read by Claude · source
“Interleukin-1 alpha inhibitor; Interleukin-1 beta inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ABBV-1451AbbViephase 11

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06972446Arthritis, Rheumatoid · United States, Canada, Czechia and more2RecruitingFeb 2027180
NCT06865105Arthritis, Psoriatic · United States, Canada, Czechia and more2RecruitingAug 2029300
NCT06718101Dermatitis, Atopic · United States, Japan, South Korea and more2Active, not recruitingMay 202783
NCT06548542Crohn Disease · United States, Austria, Belgium and more2RecruitingJan 2030590
NCT06524635Hidradenitis Suppurativa · United States2RecruitingFeb 202760
NCT06468228Hidradenitis Suppurativa · United States, Argentina, Australia and more3Active, not recruitingDec 20261,400
NCT06257875Colitis, Ulcerative · United States, Australia, Austria and more2Active, not recruitingSep 2027156
NCT06067568Healthy Volunteers · United States1CompletedFeb 26, 202450
NCT05139602Hidradenitis Suppurativa · United States, Australia, Canada and more2Active, not recruitingDec 2027210
NCT02384538Osteoarthritis2CompletedJul 2016132
NCT02087904Osteoarthritis, Knee2CompletedJun 7, 2016350
NCT01668511Osteoarthritis · United States1CompletedOct 201336

How it is read

Names in the registry

  • “Lutikizumab”, 9 entries
  • “ABT-981”, 3 entries
  • “Lutikizumab Dose A”, 1 entry
  • “Lutikizumab Dose B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.